AstraZeneca stops PhIIa trial of inhaled asthma drug with Pieris, cratering the Boston biotech's shares
After culling a HER2 drug last summer to focus on an inhaled asthma med with AstraZeneca, Pieris Pharmaceuticals appears to be on thin ice with …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
